ALDOCLOR-250 (chlorothiazide; methyldopa) by Merck & Co. is clinical pharmacology: the mechanism of the antihypertensive effect of thiazides is unknown. Approved for pregnancy, just, heart failure and 2 more indications. First approved in 1968.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
ALDOCLOR-250 is a fixed-dose combination tablet of chlorothiazide (a thiazide diuretic) and methyldopa (a centrally-acting antihypertensive) approved in 1968. It treats hypertension and heart failure by reducing blood pressure through renal sodium/chloride excretion and peripheral vasodilation. The combination addresses multiple pathways of hypertension: chlorothiazide acts on the distal renal tubule to increase natriuresis, while methyldopa centrally inhibits sympathetic outflow.
Product is in late-stage lifecycle with limited commercial runway; team focus likely on defending existing market share and managing transition to generic competitors rather than growth initiatives.
CLINICAL PHARMACOLOGY: The mechanism of the antihypertensive effect of thiazides is unknown. Chlorothiazide does not usually affect normal blood pressure. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are…
Worked on ALDOCLOR-250 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ALDOCLOR-250 offers limited career growth potential due to its mature, declining lifecycle status and minimal linked job openings. This role suits professionals seeking stable, defensive portfolio management experience or transition positions before assignment to growth-stage assets.